|
|
Line 79: |
Line 79: |
| <td>2. Scaffold categorization</td> | | <td>2. Scaffold categorization</td> |
| <td>ROSETTA protocol</td> | | <td>ROSETTA protocol</td> |
− | <td>The scaffold describes the rough layout of the synthetase. We downloaded the scaffold <a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=1j1u">1J1U </a>, the aaRS of <i> Methalonococcus janaschii </i> as a template, and then relaxed its structure to improve the outcome of the ROSETTA algorithm.</td> | + | <td>The scaffold describes the rough layout of the synthetase. We downloaded the scaffold <a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=1j1u">1J1U </a>, the aaRS of <i Methalonococcus janischii </i> as a template, and then relaxed its structure to improve the outcome of the ROSETTA algorithm.</td> |
| </tr> | | </tr> |
| <tr> | | <tr> |
Line 201: |
Line 201: |
| <li> <a href="https://www.rosettacommons.org/demos/latest/tutorials/prepare_ligand/prepare_ligand_tutorial"> </a>“.params”-file: </br> | | <li> <a href="https://www.rosettacommons.org/demos/latest/tutorials/prepare_ligand/prepare_ligand_tutorial"> </a>“.params”-file: </br> |
| A conformer ensemble has to be generated using information about the ligand, as the non-canonical amino acids are not generally available in databases like <a href=""http://www.rcsb.org/pdb/home/home.do>PDB</a>, making it necessary to build them manually | | A conformer ensemble has to be generated using information about the ligand, as the non-canonical amino acids are not generally available in databases like <a href=""http://www.rcsb.org/pdb/home/home.do>PDB</a>, making it necessary to build them manually |
− | using tools like <a href="https://pymol.org/2/">pymol</a><a href="https://avogadro.cc/">Avogadro</a> or <a href="http://www.cambridgesoft.com/software/overview.aspx">Chemdraw</a>. Using these tools, files can be saved in the desired format. The ligand needs to be specified in the “.sdf”, “.mol” or “.mol2” file format. Such a | + | using tools like <a href="https://pymol.org/2/">pymol</a><a href="https://avogadro.cc/">Avogadro</a> or <a href="http://www.cambridgesoft.com/software/overview.aspx">Chemdraw</a>. Using these tools, |
| + | files can be saved in the desired format. The ligand needs to be specified in the “.sdf”, “.mol” or “.mol2” file format. Such a |
| file can be obtained automatically by converting the relevant information from a “.pdb” file, if available. This conversion process usually also involves augmenting the data with hydrogen atoms | | file can be obtained automatically by converting the relevant information from a “.pdb” file, if available. This conversion process usually also involves augmenting the data with hydrogen atoms |
− | in case they are missing from the “.pdb” file. Alternatively, the ligand can be designed using SMILES or manually using tools such as Avogadro, as we did. In the next step, the ligand file is used | + | in case they are missing from the “.pdb” file. Alternatively, the ligand can be designed using "Simplified Molecular Input Line Entry Specification" <a href="http://daylight.com/smiles/">(SMILES)</a> or manually using tools such as <a href="https://avogadro.cc/">Avogadro</a>, as we did. In the next step, the ligand file is used |
| to create a conformer ensemble that is in turn used to create a Rosetta parameter (“.params”) file. In addition to the specific names of all atoms present in the ligand, this parameter file also | | to create a conformer ensemble that is in turn used to create a Rosetta parameter (“.params”) file. In addition to the specific names of all atoms present in the ligand, this parameter file also |
| stores all bonds between the individual atoms, including the binding angles and binding distances. Rosetta cannot generate the conformer ensemble by itself, so an additional tool is needed. | | stores all bonds between the individual atoms, including the binding angles and binding distances. Rosetta cannot generate the conformer ensemble by itself, so an additional tool is needed. |
Line 253: |
Line 254: |
| We used the “1j1u”-scaffold from PDB for our matching step. The “1j1u.pdb”-file contains the Tyrosyl-tRNA-synthetase, which is labeld under “Chain A”, the orthogonol tRNA under “Chain B” and the natural ligand Tyrosyl. For our project, we deleted the natural ligand and “Chain B”, because it was not neccerary to change their structure or sequence and it was a way to save computer time and power. | | We used the “1j1u”-scaffold from PDB for our matching step. The “1j1u.pdb”-file contains the Tyrosyl-tRNA-synthetase, which is labeld under “Chain A”, the orthogonol tRNA under “Chain B” and the natural ligand Tyrosyl. For our project, we deleted the natural ligand and “Chain B”, because it was not neccerary to change their structure or sequence and it was a way to save computer time and power. |
| | | |
− | We designed the ligands manually by usingin Avogadro, and for the .cst-file, we choose the default matching algorithm for simulations of both amino acids. | + | We designed the ligands manually by using Avogadro, and for the .cst-file, we choose the default matching algorithm for simulations of both amino acids. |
| </article> | | </article> |
| </div> | | </div> |
Line 363: |
Line 364: |
| Due to the IPTC-induced promoter, we used variants without IPTG, and with 5 mM, 10 mM, and 15 mM added IPTS for all plasmids for the kanamycine resistance. | | Due to the IPTC-induced promoter, we used variants without IPTG, and with 5 mM, 10 mM, and 15 mM added IPTS for all plasmids for the kanamycine resistance. |
| We chose additional variants with regards to the antibiotics; one variant each of kanamycine, kanamycine and chloramphenicole, and kanamycine, chloramphenicole and tetracycline. The number of resulting colonies for each variant are summarized in figure X. Our in vivo results show that our in silico designed enzymes did not lead to a loss of functioning. | | We chose additional variants with regards to the antibiotics; one variant each of kanamycine, kanamycine and chloramphenicole, and kanamycine, chloramphenicole and tetracycline. The number of resulting colonies for each variant are summarized in figure X. Our in vivo results show that our in silico designed enzymes did not lead to a loss of functioning. |
− | | + | We ordered seven synthetase sequences of NPA via IDT, and four synthetase sequences of CBT-Asparagine by courtesy of Genscript, where we had previously |
| + | won a grant of 500€. Due to problems on the part of IDT, the sequences for NPA could not be synthetized. We still provide the sequences for further use below. |
| + | All further descriptions therefore refer to the synthetase sequences for CBT-Asparagine. </br> |
| + | Unfortunately, we were not able to amplify the four sequences or clone them into the detection system pSB3T5. A test digestion revealed that the length of the |
| + | sequence in the plasmid puk57, which was the plasmid delivered by Genscript, did not correspond to the sequence length ordered. Therefore, we disregarded synthetase candidate number 1 |
| + | for further tests. </br> |
| + | For the remaining three sequences, we instead utilized the positive-negative selection plasmids for validation of our syntheses. |
| + | After the first, positive selection cycle, colonies formed only if the non-canonical amino acid was present. |
| + | Thus, through the positive selection, we could show that the synthetase did not lead to the loss of functioning of the enzyme. |
| + | To show specificity, we conducted a negative selection as well. We managed to clone the synthetases into the negative selection plasmid, |
| + | but were not able to verify this selection cycle. Therefore, further tests are needed to validate the specificity of the synthetases. |
| </div> | | </div> |
| </div> | | </div> |
Results
Results in silico
We used this algrithm to simulate the evolution of the tyrosyl-tRNA with the amino acids Nitrophenylalanine and CBT-ASP
We obtained 13 synthetase sequences for CBT-ASP, and 43 sequences for NPA, which fit well into the binding site according to the ROSETTA score.
Results in vivo
In order to test the functionality and specificity of our modeled aaRS, we translated a selection of the most promising amino acid sequences into DNA sequences optimized for E.coli and ordered them via gene synthesis. We then used a positive-negative selection system for characterization. The experiment proceeds as follows:
Due to problems with regards to the protein- and salt-concentration, we retransformed the gensyntheses which had been cloned into pSB1C3. In a next step, these syntheses were cotransformed in E.coli(BL21) with our positive selection plasmid.
With regards to CBT2, only the original colony could be transformed. From CBT4 and CBT5, were used each originally isolated clone and its retransformed counterpart.
Due to the IPTC-induced promoter, we used variants without IPTG, and with 5 mM, 10 mM, and 15 mM added IPTS for all plasmids for the kanamycine resistance.
We chose additional variants with regards to the antibiotics; one variant each of kanamycine, kanamycine and chloramphenicole, and kanamycine, chloramphenicole and tetracycline. The number of resulting colonies for each variant are summarized in figure X. Our in vivo results show that our in silico designed enzymes did not lead to a loss of functioning.
We ordered seven synthetase sequences of NPA via IDT, and four synthetase sequences of CBT-Asparagine by courtesy of Genscript, where we had previously
won a grant of 500€. Due to problems on the part of IDT, the sequences for NPA could not be synthetized. We still provide the sequences for further use below.
All further descriptions therefore refer to the synthetase sequences for CBT-Asparagine.
Unfortunately, we were not able to amplify the four sequences or clone them into the detection system pSB3T5. A test digestion revealed that the length of the
sequence in the plasmid puk57, which was the plasmid delivered by Genscript, did not correspond to the sequence length ordered. Therefore, we disregarded synthetase candidate number 1
for further tests.
For the remaining three sequences, we instead utilized the positive-negative selection plasmids for validation of our syntheses.
After the first, positive selection cycle, colonies formed only if the non-canonical amino acid was present.
Thus, through the positive selection, we could show that the synthetase did not lead to the loss of functioning of the enzyme.
To show specificity, we conducted a negative selection as well. We managed to clone the synthetases into the negative selection plasmid,
but were not able to verify this selection cycle. Therefore, further tests are needed to validate the specificity of the synthetases.
References
Liu, W., Brock, A., Chen, S., Chen, S., Schultz, P. G. ,(2007). Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nature methods, 4(3), 239-244.
Richter, F., Leaver-Fay, A., Khare, S. D., Bjelic, S., Baker, D. (2011). De novo enzyme design using Rosetta3. PloS one, 6(5): e19230.
Simons, K. T., Kooperberg, C., Huang, E., Baker, D. (1997). Assembly of protein tertiary structures from fragments with similar local sequences using simulated annealing and Bayesian scoring functions. Journal of molecular biology, 268(1), 209-225.